Insys Therapeutics to Report Second Quarter 2013 Financial Results on August 13

Marketwired

PHOENIX, AZ--(Marketwired - Jul 30, 2013) - Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that develops and commercializes innovative supportive care products, today announced that it will report its financial results for the second quarter of 2013 on Tuesday, August 13, 2013 before the open of U.S. financial markets. Following the release of the financial results, members of the Insys management team, including President and Chief Executive Officer Michael L. Babich and Chief Financial Officer Darryl S. Baker, will host a conference call to discuss the results and provide updates on the business at 11:00 a.m. ET. A live webcast and replay of the call will be available at www.insysrx.com.

To participate in the conference call, dial 888-539-3612 (U.S.) or 719-457-2689 (International), passcode 9093533. A telephone replay will be available shortly after the completion of the call at 888-203-1112 (U.S.) or 719-457-0820 (International), passcode 9093533.

About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.

Contact:
Company
Darryl S. Baker
Chief Financial Officer
Insys Therapeutics, Inc.
(602) 910-2617

Investor
John Woolford
Managing Director
Westwicke Partners, LLC
(443) 213-0506
View Comments (0)